Case File
efta-02558517DOJ Data Set 11OtherEFTA02558517
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02558517
Pages
7
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Barrett, Paul S
Sent:
Wednesday, August 15, 2012 6:03 PM
To:
Jeffrey Epstein
Cc:
Giuffrida, David
Subject:
To Do - : NEW HY RMBS - $12.5mm of BSABS 04-AC6 M1 @ $49-16 (7.03% yield/2.81
dum)
Why we think this bond is compelling:
=OD
</=pan>Deal still has ove=collateralization: There :=17;s currently 51.3mm overcollateralization in the deal.&=bsp;
Overcollateralization (CC), which is essentially excess mortgages ove= the amount of bonds issued, has been increasing
since April 2012<=u>. This is a function of the underlying mortgages bearing fixed coupons=while the issued bonds are
low margin 1ML floaters. The excess int=rest generated from this is used to pay down the senior classes in the dea=
thus reducing the relative amount of bonds outstanding vs mortgages=outstanding. Thus OC is the first line of defense
against credit l=sses. That's why the most junior class in the deal, the B3s,=have not taken a principal write-down to
date.
=OD
</=pan>Relatively short d=ration across all scenarios- &n=sp;
HPI Updated LTV = 85%<=pan style="font-
size:10.0pt;font-family:"Calibri","sans=serif";color:e1F497D">
-<=pan style="font:7.0pt "Times New Roman""> &=bsp;
=span style="font-size:10.0pt;font-family:"Calibri","san=-
serif";color:e1F497D">94 months seasoned
-
= 681 FICO
=0A••Source: Bloomberg
=OA
BSABS 20O4-AC6 Ml Offered @ 49-164p
atd>
<=d width="168" nowrap="" valign="bottom"
style="width:126.05pt;pa=ding:0in 5.4pt 0in 5.4ptheight:16.5pt">
width="50" nowrap="" valign="bottom" style="width:37.5pt;paddi=g:0in 5.4pt 0in
5.4pt;height:7.05pt">
BOND DESCRIPTION
3.5 =amp 20 5 CPR
6 CPR
Default Rate
EFTA_R1_01718249
EFTA02558517
=OD 6.5 for 30 4 CDR
=OD 6 for 365 for 124.5 CDR
5 for 36 4 CDR
=OD
Original Face:<=span>
=span style="font-size:8.0pt;font-family:"Arial","sans-s=rif";color:#1F497D">12,500,000
=td width="50" nowrap="" valign="bottom" style="width:37.5pt;padd=ng:0in 5.4pt 0in 5.4pt;height:13.35pt"> Default
Severity
=OA 65 for 36 60 for 12 55
60 ramp 18 65 60 ramp 12 55
55 ramp 12 60 55<=p>
Current Face:<=span>
=span style="font-size:8.0pt;font-family:"Arial","sans-s=rif";color:#1F497D">2,796,053
<=d width="50" nowrap="" valign="bottom" style="width:37.5pt;paddi=g:0in 5.4pt 0in 5.4pt;height:13.35pt"> Delinq
Advance (% of P&I)
85
=OA
Bond Type:
Alt-A Men Floater (1ML =#43; 67bps)
Balance Forgiveness
0.02 for 20 0 Current Balance
0.02 for 20 0 Current Balance</=:p>
=OD Ratings (S&a=p;P/Moodys/Fitch):
B-/Ca/-=/span>
=OD
=td width="168" nowrap="" valign="bottom" style="width:126.05pt;p=dding:0in 5.4pt 0in
5.4pt;height:13.35pt">
0.916%<=:p>
</=d>
0in 5.4pt;height:14.15pt">
=OA
Yield @ Base Case
=td width="192" nowrap="" valign="bottom" style="width:144.3pt;pa=ding:0in 5.4pt
2
EFTA_R1_01718250
EFTA02558518
7.034%
=OA
=0APrice @ 49.16
Stress Case<=:p>
Base Case
=OA Recovery=Case
<=pan style="font-size:8.0ptfont-family:"Arial","sans-serincolor:black">WAL @ Base Case
=0A=.0A
4.66
Yield
=0D -0.858
7.034
12.928
<=tr>
Aug12 to Sep20
-177
61=
1194
3.09
2.81
2.85
<=tr>
=OA
13.83%
WAL
=OD 4.81
4.66
5.18
3
EFTA_R1_01718251
EFTA02558519
</=r>
60-E Delinquencies
=OA 28.31
Principal Window
Aug12 to lun20<=:p>
Aug12 to Sep20
=OA 0.49x
Pr=ncipal Writedown
59.98%
=OD
<=pan style="font-size:8.0pt;font-family:"Arial","sans-se=if";color:black">47.98%
35.90%<=:p>
=td width="233" nowrap="" valign="bottom" style="width:174.75pt;p=dding:0in 5.4pt Din 5.4pt;height:11.8pt">
Total Collat Loss
6..04%
5.73%
5.28%
<= class="MsoNormal">UNDERLYING COLLATERAL DESCRIP=ION
Total Liquidation<=:p>
28.10%
25.20%=/p>
Average Loan Balance ($,=00s)
216
<=td> <=d width="177" nowrap="" valign="bottom" style="width:132.8ptpad=ing:0in 5.4pt 0in 5.4pt;height:13.35pt">
Loan C=unt
429
</=d> <=d width="177" nowrap="" valign="bottom" style="width:132.8ptbac=ground:#D99795;padding:0in 5.4pt Din
5.4pt;height:13.35pt">
4
EFTA_R1_01718252
EFTA02558520
HISTORICAL PERFORMANCE<=o:p>
<=td> Mortgage Typ=
Alt-A 30yr Fix
=OD
=OD
1 MOS
=/td> 3 MOS</=:p>
Wtd Avg Mortgage Coupon
=OD 6.200%
CPR
0.09
=OD 2.64
6.44<=p>
Wtd Avg FICO Score</=:p>
681
CDR
0.00
=0D
<=pan style="font-size:8.0pefont-family:"Arial","sans-se=if";colOr:#1F497D">1.44
2.45<=:p>
Wtd Av= Ork Loan-to-Value
75.38%
SEV
=1W> NA
NA
42.48
5
EFTA_R1_01718253
EFTA02558521
</=r>
HPI Adj LTV
=OA
=OA
=OD
Weighted Avg Loan Age=/p>
=OA
94
=OD
Owner Occupied<=span>
=span style="font-size:8.0pt;font-family:"Arial","sans-s=rif";color:141F497D">81.37
=0A
=0ATop 1 Geo Conce=tration
CA 22%
=OD
=OD
T=p 2 Geo Concentration
NY 22%</=:p>
=OA
=OD
Top 3 Geo Concentration
=OD FL 10%
=OA
=OD
Always Current (24 mos)
=OA
57.05%
=p class="MsoNormal">IMPORTANT DISCLAIMER:
Non-agency RMBS is a complex fixed income product and is not suitabl= for all investors. Please note that while desk
assumptions are dr=ven by a number of collateral and macro factors, the historical p=rformance of a deal is not
indicative of its future performance.&nbs=; Additionally, this message is a product of sales and trading and is not =
research report. Other key risks to consider are outlined below:<=:p>
=nbsp; All=investments are subject to possible loss of principal
<=span>Non-Agency bonds may ha=e limited liquidity and clients should be aware that the secondary market =or
mortgage-backed securities has experienced periods of illiquidity=and may do so in the future. Illiquidity means that
there may not be any=purchasers for your class of certificates. Although any class of certifi=ates may experience
illiquidity, it is more likely that classes that are l=wer in the capital structure and non-investment grade related may
ex=erience greater illiquidity than more senior, investment-grade rated class=s.
6
EFTA_R1_01718254
EFTA02558522
- &nb=p;
High Yield Non-Agency bonds are speculative non-investmen= grade bonds that have higher risk of default
or other adverse credit even=s which are appropriate for high risk investors only
qtbody>
&nbs=;
This email is c=nfidential and subject to important disclaimers and conditions including o= offers for the purchase or sale
of securities, accuracy and completeness =f information, viruses, confidentiality, legal privilege, and legal
entity=disclaimers, available at http://www.jpmorgan.com/pages/disclosures/em=il.
7
EFTA_R1_01718255
EFTA02558523
Technical Artifacts (9)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Flight #
AC6Phone
2558517Phone
2558518Phone
2558519Phone
2558520Phone
2558521Phone
2558522Phone
2558523URL
http://www.jpmorgan.com/pages/disclosures/em=ilRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.